Akash Tewari
Stock Analyst at Jefferies
(1.54)
# 3,326
Out of 4,918 analysts
57
Total ratings
32.56%
Success rate
-2.56%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $7.42 | +34.77% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $44.23 | +53.74% | 4 | Apr 23, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $58.14 | +63.40% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $107.34 | +39.74% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $3.36 | +376.19% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $128.91 | +46.61% | 2 | Aug 19, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $80 | $22.95 | +248.58% | 2 | Jul 31, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Buy | $29 → $75 | $43.03 | +74.30% | 1 | Jul 16, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $994 → $1,015 | $762.33 | +33.14% | 6 | Jun 24, 2024 | |
| ALKS Alkermes | Maintains: Buy | $42 → $50 | $26.55 | +88.32% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $37.77 | +98.57% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $16.26 | +90.71% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $935 → $937 | $558.87 | +67.66% | 4 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $23.49 | +66.03% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $7.11 | +153.16% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $672.91 | -23.76% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.47 | +229.07% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $79.29 | +57.65% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $12.57 | -12.49% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.26 | +1,249.21% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $36.69 | +104.42% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $302.17 | -50.03% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $37.26 | -24.85% | 3 | Oct 7, 2021 |
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $7.42
Upside: +34.77%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $44.23
Upside: +53.74%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $58.14
Upside: +63.40%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $107.34
Upside: +39.74%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $3.36
Upside: +376.19%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $128.91
Upside: +46.61%
Apellis Pharmaceuticals
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $22.95
Upside: +248.58%
Ionis Pharmaceuticals
Jul 16, 2024
Upgrades: Buy
Price Target: $29 → $75
Current: $43.03
Upside: +74.30%
Eli Lilly and Company
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $762.33
Upside: +33.14%
Alkermes
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $26.55
Upside: +88.32%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $37.77
Upside: +98.57%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $16.26
Upside: +90.71%
Nov 28, 2023
Maintains: Buy
Price Target: $935 → $937
Current: $558.87
Upside: +67.66%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $23.49
Upside: +66.03%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $7.11
Upside: +153.16%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $672.91
Upside: -23.76%
Jun 7, 2023
Initiates: Buy
Price Target: $18
Current: $5.47
Upside: +229.07%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $79.29
Upside: +57.65%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $12.57
Upside: -12.49%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.26
Upside: +1,249.21%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $36.69
Upside: +104.42%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $302.17
Upside: -50.03%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $37.26
Upside: -24.85%